Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses. ##STR00001##

The present invention relates to a method for preparing the compound of formula IV, compound of formula XI, and acalabrutinib, a new generation of bruton tyrosine kinase (BTK) inhibitor.

##STR00001##

Compounds of formula (I), wherein A, R, W.sup.1, W.sup.2, W.sup.3, W.sup.4, W.sup.5, W.sup.6, L, Q, R.sup.x and u have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

##STR00001##

Compounds of formula (I), wherein A, R, W.sup.1, W.sup.2, W.sup.3, W.sup.4, W.sup.5, W.sup.6, L, Q, R.sup.x and u have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

##STR00001##

The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.

The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.

Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.

Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.

The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.

The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.